Drug Sentece Context
Table 1. Analysis of context sentence of dupilumab gene in 1 abstracts.
|32330323||Dupilumab is a fully human monoclonal antibody against the alfa subunit of interleukin (IL)-4 receptor that blocks signalling from both IL-4 and IL-13, which are key type 2 cytokines in the pathophysiology of atopic dermatitis (AD). […] In a paper of Deleuran et al. the authors showed long term safety and efficacy of dupilumab; they reported viral upper respiratory tract infection, cough and influenza in about 2% of patients.|
|32339362||Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 (IL-4) and IL-13. […] Dupilumab is approved for inadequately controlled moderate-to-severe AD.1.|
|32362061||In particular, there are no current clinical data about the interference exerted by dupilumab, a biologic drugs blocking IL-4 and IL-13, used for adult atopic dermatitis. […] Furthermore, dupilumab has been proved to be efficacious also in exacerbations of asthma, and it is known that viral infections can worsen asthma. […] Therefore, the current data seem to suggest that treatment with dupilumab should not be stopped during COVID-19 pandemic.|
|32386431||We have read with great interest the letter of the European Task Force on Atopic Dermatitis (ETFAD) on SARS-CoV-2-infection and atopic dermatitis published in JEADV (March 2020)1 in which the authors state: “Targeted treatment selectively interfering with type-2 inflammation such as dupilumab is not considered to increase the risk for viral infections and might thus be preferred …in a situation such as COVID-19 pandemic”.1.|
|32417136||A patient with severe CRSwNP, asthma, and NSAIDS received dupilumab treatment.|
|32458536||Apremilast, acitretin and dupilumab, have favorable safety data, and may be safely initiated and continued in uninfected patients.|